natgillin/translations-raw huggingface dataset:
Therefore, antiplatelet therapies should not be discontinued (see section 5.1). 
Zato antiagregacijske terapije ne smemo ukiniti (glejte poglavje 5.1).
Cyclo-oxygenase-2 is an enzyme that increases at inflammatory sites and in abnormally growing cells. 
Ciklooksigenaza-2 je encim, katerega raven se zveča na mestih vnetja in v nenormalno rastočih celicah.
For any information about this medicine, please contact the local representative of the Marketing 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika
The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. 
Presnovna zmogljivost bolnikov z blago do zmerno okvaro je najbolje korelirala z vrednostjo albumina.
• Hypersensitivity to the active substance or to any of the excipients (see section 6.1). 
• Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov (glejte poglavje 6.1).
Therefore, the combination should be administered with caution, especially in the elderly. 
Zato je treba takšno kombinacijo posebno še pri starejših osebah aplicirati zelo previdno.
The maximum recommended daily dose is 800 mg. 
Največji priporočeni dnevni odmerek je 800 mg.
Onsenal works by inhibiting COX-2, to which such dividing cells are sensitive. 
Zdravilo Onsenal deluje tako, da zavre COX-2, na katerega so takšne deleče se celice občutljive.
Make sure that your doctor knows before you start taking Onsenal: - if you have conditions which increase your risk of heart disease such as high blood pressure, 
Preden začnete jemati Onsenal, poskrbite, da bo zdravnik vedel: - če imate bolezni, ki povečujejo tveganje za bolezen srca, kot naprimer visok krvni tlak,
- if you have had a serious allergic reaction or a serious skin reaction to any medicines 
- če ste imeli resno alergijsko reakcijo ali resno kožno reakcijo na katerokoli zdravilo
Two isoforms, COX-1 and COX-2, have been identified. 
Ugotovljeni sta dve izoobliki, COX-1 in COX-2.
What ONSENAL looks like and contents of the pack 
Izgled zdravila Onsenal in vsebina pakiranja
The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 2.0, predstavljeni v modulu 1.8.1. vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in da deluje, preden da zdravilo v promet in toliko časa, kolikor bo zdravilo v
As a result, the frequencies of these adverse drug reactions cannot be reliably determined. 
Zaradi tega pogostnosti teh neželenih učinkov ni mogoče zanesljivo ugotoviti.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the version dated 28 February 2005 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP. 
Imetnik dovoljenja za promet z zdravilom se obvezuje, da bo opravil dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, ki je bil sprejet v različici z dne, 28. februarja 2005 načrta za obvladovanje tveganja (RMP), predstavljenem v modulu 1.8.2. vloge za pridobitev dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP, s katerimi soglaša Odbor za zdravila za uporabo v humani medicini (CHMP).
Plasma protein binding is about 97% at therapeutic plasma concentrations and celecoxib is not preferentially bound to erythrocytes. 
Pri terapevtskih plazemskih koncentracijah je vezava na beljakovine v plazmi približno 97-odstotna; celekoksib se ne veže prednostno na eritrocite.
Celecoxib was excreted in rat milk. 
Celekoksib se je izločal v mleko podgan.
Like all medicines, ONSENAL can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Onsenal neželene učinke, ki pa se ne pojavijo pri vseh
Celecoxib is a weak inhibitor of CYP2D6. 
Celekoksib je šibek zaviralec CYP2D6.
Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. 
Celekoksib se izloča v mleku doječih podgan v koncentraciji, ki je podobna koncentraciji v plazmi.
In animals, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses. 
Pri živalih je izpostavljenost celekoksibu med zgodnjim embrionalnim razvojem povzročila izgube zarodkov pred ugnezdenjem in po njem.
The main metabolites found in the circulation have no detectable COX-1 or COX-2 activity. 
Glavni presnovki v obtoku nimajo ugotovljive aktivnosti na COX-1 ali COX-2.
COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). 
COX-2 je vpletena tudi v ovulacijo, ugnezdenje zarodka in zaprtje arterioznega duktusa, uravnavanje delovanja ledvic in funkcije centralnega živčnega sistema (indukcija zvišane telesne temperature, zaznavanje bolečine in kognitive funkcije).
Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1). 
Bolnike s pomembnimi dejavniki tveganja za srčnožilne dogodke (npr. hipertenzija, hiperlipidemija, diabetes mellitus, kajenje) lahko s celekoksibom zdravimo le po skrbnem premisleku (glejte poglavje
Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differing from arylamine sulfonamides (e.g. sulfamethoxizole and 
Celekoksib je diaril-substituiran pirazol, kemično podoben drugim nearilaminskim sulfonamidom (npr. tiazidom, furosemidu), a drugačen od arilaminskih sulfonamidov (npr. sulfametoksazola in
Diaphragmatic hernia was also seen in a peri-post natal toxicity study in rats, which included exposure during the organogenetic period. 
Diafragmalno hernijo so ugotovili tudi v peri-/postnatalni študiji toksičnih učinkov na podganah, v kateri so bile živali izpostavljene zdravilu tudi med obdobjem organogeneze.
In the event of elderly patients with mild to moderate cardiac dysfunction requiring therapy, special care and follow up is warranted. 
Pri starejših bolnikih z blago do zmerno disfunkcijo srca, ki zahteva zdravljenje, sta potrebna posebna skrb in spremljanje.
In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. 
Če obstaja sum na preveliko odmerjanje, je treba zagotoviti ustrezno podporno medicinsko oskrbo, npr. izpiranje želodca, kliničen nadzor in, če je treba, simptomatsko zdravljenje.
The greatest reduction was observed in patients treated with celecoxib 16 mg/kg/day, which corresponds to the recommended adult FAP dose of 800 mg daily. 
Največje zmanjšanje so zabeležili pri bolnikih, ki so dobivali celekoksib v odmerku 16 mg/kg/dan, kar ustreza priporočenemu odmerku za odrasle s FAP, ki je 800 mg na dan.
Celecoxib is contraindicated in pregnancy and in women who can become pregnant unless using an effective method of contraception (see section 4.3). 
Celekoksib je kontraindiciran med nosečnostjo in pri ženskah, ki bi lahko zanosile, če ne bi uporabljale učinkovite kontracepcijske zaščite (glejte poglavje 4.3).
Cardiovascular Safety - Long-Term Studies Involving Subjects With Sporadic Adenomatous Polyps: Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). 
Srčnožilna varnost - dolgoročne študije preiskovancev s sporadičnimi adenomatoznimi polipi: S celekoksibom sta bili izvedeni dve študiji preiskovancev s sporadičnimi adenomatoznimi polipi: preskušanje APC (Adenoma Prevention with Celecoxib) in preskušanje PreSAP (Prevention of Spontaneous Adenomatous Polyps).
Studies in animals (rats and rabbits) have shown reproductive toxicity (see sections 4.3 and 5.3). 
Študije na živalih (podganah in kuncih) so pokazale učinke na sposobnost razmnoževanja (glejte poglavji 4.3 in 5.3).
There is no clinical experience of overdose in clinical trials. 
Kliničnih izkušenj s prevelikim odmerjanjem iz kliničnih preskušanj ni.
In clinical studies where Onsenal was taken for up to 3 years to prevent spontaneous colon polyps, the following additional side effects have been observed (side effects marked with an asterisk were more common in these studies than in arthritis studies): 
V kliničnih študijah, v katerih so bolniki do 3 leta dobivali zdravilo Onsenal za preprečevanje spontanih polipov na debelem črevesu, so zabeležili naslednje dodatne neželene učinke (z zvezdico označeni neželeni učinki so bili v teh študijah pogostejši kot v študijah pri artritisu):
The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. 
Razlika v antitrombocitni aktivnosti med nekaterimi NSAID, ki zavirajo COX-1, in selektivnimi zaviralci COX-2 bi lahko bila klinično pomembna pri bolnikih, ki jih ogrožajo trombembolične reakcije.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu/, kjer lahko najdete tudi povezave do drugih spletnih strani o redkih boleznih in zdravljenju.
diabetes, high cholesterol or if you smoke you should discuss with your doctor whether Onsenal is suitable for you 
sladkorno bolezen, visok holesterol, ali če kadite, se morate z zdravnikom posvetovati, ali je
Familial Adenomatous Polyposis (FAP) is a genetic disease resulting from an autosomal dominant genetic alteration of a tumor suppressor gene, the adenomatous polyposis coli (APC) gene. 
Familiarna adenomatozna polipoza (FAP) je genetska bolezen; njen vzrok je avtosomna dominantna sprememba gena za supresijo tumorjev, t. i. gena adenomatozne polipoze kolona (APK).
Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see 
Onsenal je indiciran za zmanjšanje števila adenomatoznih intestinalnih polipov pri familiarni adenomatozni polipozi (FAP) kot dodatek operaciji in nadaljnjemu endoskopskemu nadzoru (glejte
Do not store your capsules above 30°C. 
Kapsule shranjujte pri temperaturi do 30 °C.
As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. 
Kot vsa nesteroidna protivnetna zdravila lahko tudi celekoksib povzroči pojav hipertenzije ali poslabšanje obstoječe hipertenzije; oboje lahko pripomore k večji incidenci srčnožilnih dogodkov.
- if you have had an allergic reaction to any of the ingredients of Onsenal - if you have had an allergic reaction to a group of medicines called “sulphfonamides”. 
- če ste kdaj imeli alergijsko reakcijo na katerokoli sestavino zdravila Onsenal - če ste kdaj imeli alergijsko reakcijo na zdravila, ki jih imenujemo "sulfonamidi".
Examples of medicinal products which are metabolised by CYP2C19 are diazepam, citalopram and imipramine. 
Zgledi zdravil, ki se presnavljajo s CYP2C19, so diazepam, citalopram in imipramin.
Stop taking the capsules and tell your doctor immediately… If you have an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing 
Nehajte jemati kapsule in zdravniku takoj povejte ... - če dobite alergijsko reakcijo, npr. izpuščaj na koži, oteklost obraza, piskajoče dihanje ali težave
The MAH has previously committed to undertake a “Phase III placebo-controlled trial with celecoxib in genotype positive subjects with Familial Adenomatous Polyposis” (CHIP trial, Protocol A3191193) to generate further efficacy and safety data. 
Imetnik dovoljenja za promet se je predhodno zavezal, da izvede “S placebom nadzorovano preskušanje III. faze s celekoksibom pri genotipsko pozitivnih preiskovancih s familiarno adenomatozno polipozo” (preskušanje CHIP , protokol A3191193), s katero pridobi dodatne podatke o
Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy. 
Zato je treba med uvedbo celekoksiba in ves čas zdravljenja natančno kontrolirati krvni tlak.
Onsenal can be taken with low dose acetylsalicylic acid (aspirin). 
Zdravilo Onsenal lahko jemljete z majhnimi odmerki acetilsalicilne kisline (Aspirina).
However, patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery. 
Vendar naj bolniki, ki med jemanjem celekoksiba doživljajo omotico, vrtoglavico ali zaspanost, ne vozijo in ne upravljajo strojev.
The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in Table 1. 
Neželeni učinki, opaženi s celekoksibom v teh dodatnih študijah, so se skladali s tistimi pri bolnikih z osteoartritisom in revmatoidnim artritisom, naštetimi v preglednici 1.
The European Medicines Agency (EMA) will review any new information on the medicine every year and this leaflet will be updated as necessary. 
Evropska agencija za zdravila (EMA) bo vsako leto ponovno pregledala vse nove podatke o zdravilu in posodobila navodilo za uporabo, če bo potrebno.
As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients or elderly patients) when ACE inhibitors or angiotensin II receptor antagonists are combined with NSAIDs, including celecoxib. 
Za NSAID-e velja, da se tveganje akutne ledvične insuficience, ki je običajno reverzibilna, lahko pri nekaterih bolnikih s prizadeto funkcijo ledvic (npr. dehidrirani ali starejši bolniki) poveča v primeru, da kombiniramo zaviralce ACE ali antagoniste receptorjev angiotenzina II z NSAID-i, vključno s celekoksibom.
− Oedema (water retention that can cause swelling) − Enlarged or inflamed prostate, prostate specific antigen increased (lab test) 
- edemi (zastajanje vode, ki lahko povzroči otekanje) - povečanje ali vnetje prostate, zvišanje za prostato specifičnega antigena (laboratorijska
Onsenal 400 mg capsules contain lactose (99.6 mg). 
Kapsule Onsenal 400 mg vsebujejo laktozo (99,6 mg).
complications fracture * Hypertension, vomiting and diarrhoea are included in Table 2 because they were reported more frequently in these studies, which were of 3-year duration, compared to Table 1, which includes adverse reactions from studies of 12-week duration. 
* Hipertenzija, bruhanje in driska so vključeni v preglednico 2, ker so bili v teh, 3-letnih študijah zabeleženi pogosteje, v primerjavi s preglednico 1, ki obsega neželene učinke 12-tedenskih študij.
Treatment with celecoxib in FAP has been studied for up to 6 months and has not been shown to reduce the risk of gastrointestinal or other form of cancer or the need for surgery. 
Pri bolnikih s FAP so zdravljenje s celekoksibom proučevali do 6 mesecev; ob tem niso ugotovili, da bi zdravilo zmanjšalo tveganje za karcinom na prebavilih, druge vrste karcinom ali potrebo po operaciji.
In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the recommended daily human dose was 2 times more than the recommended daily human 
V tej zadnji študiji, je bila ob najmanjši sistemski izpostavljenosti (pri kateri se je ta anomalija pojavila pri eni sami živali) ocenjeno, da je bil mejni odmerek glede na priporočeni dnevni odmerek za človeka 2-krat večji od priporočenega dnevnega odmerka za človeka (800 mg).
Special care should be used in such patients (see section 5.2). 
Pri takšnih bolnikih je potrebna posebna previdnost (glejte poglavje 5.2).
Onsenal 200 mg capsules contain lactose (49.8 mg). 
Kapsule Onsenal 200 mg vsebujejo laktozo (49,8 mg).
The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients since it is mainly eliminated by hepatic metabolism. 
Farmakokinetika celekoksiba pri bolnikih z ledvično okvaro niso raziskali, vendar ni verjetno, da bi bila bistveno spremenjena, ker se zdravilo izloča predvsem s presnovo v jetrih.
In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethistherone /35 microg ethinylestradiol). 
V študiji medsebojnega delovanja celekoksib ni klinično pomembno vplival na farmakokinetiko peroralnih kontraceptivov (1 mg noretisterona/35 mikrogramov etinilestradiola).
Experimental evidence shows that the mechanism(s) of action by which celecoxib leads to tumour death may be related to induction of apoptosis and inhibition of angiogenesis. 
Eksperimentalne ugotovitve kažejo, da je mehanizem, po katerem celekoksib povzroči odmrtje tumorjev, morda povezan z indukcijo apoptoze in zavrtjem angiogeneze.
Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR. 
Zato je treba pri bolnikih, ki prejemajo peroralne antikoagulante, natančno nadzirati protrombinski čas ali INR.
In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer. 
V dodatnih študijah, v katerih so kot primerjavo uporabljali neselektivna nesteroidna protivnetna zdravila, so približno 7400 bolnikov z artritisom zdravili s celekoksibom v dnevnih odmerkih do 800 mg; med njimi je bilo približno 2300 bolnikov zdravljenih 1 leto ali več.
Additional reactions have been reported from actual use of the active ingredient of Onsenal (in post-marketing experience). 
Dodatni učinki so bili opisani med dejansko uporabo zdravilne učinkovine zdravila Onsenal (v pomarketinškem obdobju).
COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established. 
COX-2 so pri človeku našli v tkivu okoli želodčnih ulkusov, a njena vloga pri celjenju ulkusov ni ugotovljena.
Onsenal is used to reduce the number of gastrointestinal polyps in patients with Familial Adenomatous Polyposis (FAP). 
Zdravilo Onsenal se uporablja za zmanjšanje števila polipov v prebavilih pri bolnikih s familiarno adenomatozno polipozo (FAP).
Caution should be exercised when combining celecoxib with warfarin and other oral anticoagulants (see section 4.5). 
Previdnost je potrebna, kadar se celekoksib kombinira z varfarinom in drugimi peroralnimi antikoagulanti (glejte poglavje
The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction. 
V obeh odmernih skupinah celekoksiba je bilo povečanje v primerjavi s placebom predvsem posledica večje incidence miokardnega infarkta.
There is further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses). 
Nadalje obstaja večje tveganje za neželene učinke v prebavilih (razjeda v prebavilih ali drugi gastrointestinalni zapleti), kadar se celekoksib uporablja sočasno z acetilsalicilno kislino (celo pri majhnih odmerkih).
Data from pooled analysis of controlled randomized trials also suggest that cardiovascular risk may be associated with the use of celecoxib compared to placebo, with evidence for differences in risk based 
Podatki kumulativne analize kontroliranih randomiziranih preskušanj tudi kažejo, da je lahko srčnožilno tveganje povezano z uporabo celekoksiba v primerjavi s placebom, z dokazi za različno
Celecoxib can be used with low dose acetylsalicylic acid, however it cannot be considered a substitute for acetylsalicylic acid for cardiovascular prophylaxis. 
Celekoksib se lahko uporablja z majhnimi odmerki acetilsalicilne kisline, vendar ne more nadomestiti acetilsalicilne kisline v kardiovaskularni profilaksi.
• Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score >10) (Class C). 
• Hudo poslabšano delovanje jeter (albumin v serumu < 25 g/l ali ocena po Child-Pughu > 10)
In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). 
Pri bolnikih z revmatoidnim artritisom celekoksib ni statistično značilno vplival na farmakokinetiko (plazemski ali ledvični očistek) metotreksata (v revmatoloških odmerkih).
Conventional embryo-foetal toxicity studies resulted in dose dependent occurrences of diaphragmatic hernia in rat foetuses and of cardiovascular malformations in rabbit foetuses at systemic exposures to free celecoxib approximately 3 times (rat) and 2 times (rabbit) higher than those achieved at the recommended daily human dose (800 mg). 
Običajne študije embrio-fetotoksičnosti so pokazale od odmerka odvisno pojavljanje diafragmalne hernije pri plodovih podgan ter kardiovaskularnih malformacij pri plodovih kuncev ob sistemski izpostavljenosti prostemu celekoksibu, ki je bila približno 3-krat večja (podgane) oz. 2-krat večja (kunci) od izpostavljenosti, dosežene s priporočenim dnevnim odmerkom za človeka (800 mg).
Concomitant use of inducers of CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of celecoxib. 
Sočasna uporaba induktorjev CYP2C9, npr. rifampicina, karbamazepina ali barbituratov, lahko zmanjša koncentracijo
Pilot Study in Juvenile FAP Patients: A total of 18 children 10 to 14 years of age who had genotype or phenotype positive FAP were treated with celecoxib 4 mg/kg/day (4 patients, compared to 2 patients treated with placebo), celecoxib 8 mg/kg/day (4 patients, compared to 2 patients treated with placebo), or celecoxib 16 mg/kg/day (4 patients, compared to 2 patients treated with placebo). 
Pilotska študija pri bolnikih z juvenilno FAP: Skupno so 18 otrok, starih od 10 do 14 let in z genotipsko ali fenotipsko pozitivno FAP, zdravili s celekoksibom 4 mg/kg/dan (4 bolniki v primerjavi z 2 bolnikoma, ki sta dobivala placebo), 8 mg/kg/dan (4 bolniki v primerjavi z 2 bolnikoma, ki sta dobivala placebo) ali 16 mg/kg/dan (4 bolniki v primerjavi z 2 bolnikoma, ki sta dobivala placebo).
Renal impairment: Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution (see sections 4.3, 4.4 and 5.2). 
Ledvična okvara: Izkušnje s celekoksibom pri bolnikih z blago ali zmerno ledvično okvaro so omejene, zato je treba takšne bolnike zdraviti previdno (glejte točke 4.3, 4.4 in 5.2).
Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib Cmax of 60% and in AUC of 130% (analogous studies have not been performed with amiodarone or other known CYP2C9 inhibitors). 
Sočasna uporaba enkratnega odmerka 200 mg celekoksiba in 200 mg flukonazola, ki je močan zaviralec CYP2C9, enkrat na dan je povzročila povprečno zvečanje Cmax celekoksiba za 60 % in njegove AUC za 130 % (analogne študije z amiodaronom ali ostalimi znanimi zaviralci CYP2C9 niso bile izvedene).